Nuvectis Pharma jumps 20% to 52-week high — here's why NVCT stock is trending

Nuvectis Pharma, Inc. NVCT shares are trending on Monday. NVCT shares surged 19.61% during Monday’s regular trading session ...

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage ...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases ...
BioWorld

Complement factor B inhibitors reported in Hansoh patent

A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.
Renal & Urology News

Complement Activation Implicated in Acute Kidney Injury

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...
BioWorld

Novartis identifies new complement factor B inhibitors

Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, ...